LAUSR

Background Drug survival rate is generally accepted as a reliable indicator of both efficacy and safety profile of a biological DMARD. Objectives To evaluate survival rates of certolizumab-pegol (CZP) in ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nrAxSpA) patients registered in HUR-BIO (Hacettepe University Rheumatology Biologic Registry). Methods HUR-BIO is a monocentric database of biologics including 2058 SpA patients (226 were prescribed CZP) by June 2017. All AS (n=142) and nrAxSpA (n=54) patients in HUR-BIO prescribed CZP at least once were enrolled in the study. Twenty-three patients who was already on CZP before admitting Hacettepe University were excluded. Patients prescribed CZP within 6 months period before analysis defined as drug continuing. Demographic, clinical and laboratory data of AS and nrAxSpa patients were evaluated. Kaplan-Meier analysis was used to estimate CZP survival rates. Results In total, 124 AS and 49 nrAxSpA patients were analysed. Baseline characteristics of patients were shown in Table. Median duration of CZP usage was 7.54 (3–26.5) months in AS and 6.27 (3–26.7) months in nrAxSpA group(p=0.53). CZP survival was similar between AS and nrAxSpA patients (figure 1). Fourty-nine (27.2%) patients had used at least one TNFi and 38 (21.9%) patients had used more than one TNFi before CZP. There was no difference in drug survival between those who used TNFi and those who did not use TNFi before CZP (figure 2). BASDAI 50 response was reached in 27.6% of AS and 36.0% of nrAxSpA patients and at the last control visit (p=0.44).Abstract SAT0274 – Table 1 Baseline demographic and clinical characteristics of patients. AS nrAxSpA p Age, years (min-max) 36.5 (18–60) 32 (18–54) 0.041 Male, n (%) 58 (46.8) 21 (42.9) 0.641 Female, n (%) 66 (53.2) 28 (57.1) Disease duration, months (min-max) 48 (3–312) 24 (3–144) 0.011 Disease duration≥5 years, n (%) 59 (47.6) 16 (32.7) 0.07 History of smoking, n (%) 79 (63.7) 26 (53.1) 0.196 History of uveitis, n (%) 9 (7.3) 3 (6.1) 0.791 Previous biological use, n (%) 59 (47.6) 26 (53.1) 0.516 Baseline BASDAI 57 (4–100) 57 (0–94) 0.495 Baseline BASFI 41 (0–100) 42 (0–94) 0.422 Baseline back pain VAS 70 (0–100) 70 (10–100) 0.961 ESR, mm/h (min-max) 15 (2–105) 13 (2–97) 0.177 CRP, mg/dL (min-max) 0.83 (0.1–18.2) 0.91 (0.1–8.32) 0.810 ESR>UL, n (%) 48 (39.7) 14 (29.8) 0.286 CRP>UL, n (%) 64 (52.9) 25 (54.39 0.866 Syndesmophytes on X-ray, n (%) 21 (16,9) 3 (6,1) 0.064Abstract SAT0274 – Figure 1 CZP survival in AS and nrAxSpA patientsAbstract SAT0274 – Figure 2 CZP survival in patients with and without history of TNFi use before CZP Conclusions In this single centre biological SpA cohort, adherence to CZP therapy seems to be high with a first year survival rate of 83% and there was no difference between AS and nrAxSpA patients. Disclosure of Interest None declared